Top

The European Journal of Health Economics

Published in:

01-05-2014 | Original Paper

Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary

Authors: Emese Herédi, Fanni Rencz, Orsolya Balogh, László Gulácsi, Krisztina Herszényi, Péter Holló, Hajnalka Jókai, Sarolta Kárpáti, Márta Péntek, Éva Remenyik, Andrea Szegedi, Valentin Brodszky

Published in: The European Journal of Health Economics | Special Issue 1/2014

Abstract

Background

There is a growing interest in policy making for using utility measures and identifying algorithms to convert disease-specific measures into utilities.

Objectives

To analyse the relationship between EQ-5D, Dermatology Life Quality Index (DLQI) and Psoriasis Area and Severity Index (PASI) in psoriasis. To transform DLQI scores, and key clinical, demographic and health service utilisation variables into utilities.

Methods

A cross-sectional questionnaire survey of 200 consecutive adult patients with moderate to severe psoriasis was carried out in two Hungarian university clinics. The relationship between the outcome measures were analysed with correlations and with the known-groups method. Bivariate and multivariate regression algorithms on EQ-5D scores were formulated.

Results

The mean age of respondents was 51 years (SD = 12.9), 68.5 % were male, and 51.5 % received biological therapy. Median EQ-5D, DLQI, and PASI scores were 0.73, 3.0, and 3.45, respectively. EQ-5D showed a moderate correlation with the DLQI and with the PASI (r _s = −0.48 and −0.43, p < 0.05). Strong correlation was found between DLQI and PASI (r _s = 0.81, p < 0.05). DLQI and PASI discriminated better among groups categorised by the localisation of the lesions than EQ-5D. Presence of psoriasis on the neck and/or décolletage was associated with the greatest health related quality of life (HRQOL) impairment. Ten variables were incorporated in a multivariate algorithm that accounted for 48.8 % of EQ-5D variance (ANOVA p < 0.001).

Conclusions

This study provided the first evidence that patients with visible psoriatic lesions have significantly worse HRQOL compared to those with non-visible lesions, measured not only with DLQI but also with EQ-5D. In addition to demographic and clinical variables, our model included health service utilisation variables related to psoriasis, and explained higher proportion of EQ-5D variance than any previous findings in the literature.

Parisi, R., Symmons, D.P., Griffiths, C.E., Ashcroft, D.M.: Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J. Invest. Dermatol. 133(2), 377–385 (2013). doi:10.1038/jid.2012.339 PubMedCrossRef

de Korte, J., Sprangers, M.A., Mombers, F.M., Bos, J.D.: Quality of life in patients with psoriasis: a systematic literature review. J. Investig. Dermatol. Symp. Proc. 9(2), 140–147 (2004). doi:10.1046/j.1087-0024.2003.09110.x PubMedCrossRef

Ahn, C.S., Gustafson, C.J., Sandoval, L.F., Davis, S.A., Feldman, S.R.: Cost effectiveness of biologic therapies for plaque psoriasis. Am. J. Clin. Dermatol. 14(4), 315–326 (2013). doi:10.1007/s40257-013-0030-z PubMedCrossRef

Brodszky, V.: Systematic Review and Analysis of Evidences on Clinical Efficacy and Cost-Effectiveness of Biological Drugs for the Treatment of Prosiasis. Corvinus University of Budapest, Department of Health Economics, Budapest, Hungary (2013)

Bronsard, V., Paul, C., Prey, S., Puzenat, E., Gourraud, P.A., Aractingi, S., Aubin, F., Bagot, M., Cribier, B., Joly, P., Jullien, D., Le Maitre, M., Richard-Lallemand, M.A., Ortonne, J.P.: What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J. Eur. Acad. Dermatol. Venereol. 24(Suppl 2), 17–22 (2010). doi:10.1111/j.1468-3083.2009.03563.x PubMedCrossRef

Lewis, V., Finlay, A.Y.: 10 years experience of the Dermatology Life Quality Index (DLQI). J. Investig. Dermatol. Symp. Proc. 9(2), 169–180 (2004). doi:10.1111/j.1087-0024.2004.09113.x PubMedCrossRef

Dakin, H.: Review of studies mapping from quality of life or clinical measures to EQ-5D: an online database. Health Qual. Life Outcomes 11, 151 (2013). doi:10.1186/1477-7525-11-151 PubMedCentralPubMedCrossRef

Norlin, J.M., Steen Carlsson, K., Persson, U., Schmitt-Egenolf, M.: Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients. Br. J. Dermatol. 166(4), 797–802 (2012). doi:10.1111/j.1365-2133.2011.10778.x PubMedCrossRef

Blome, C., Beikert, F.C., Rustenbach, S.J., Augustin, M.: Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities. Arch. Dermatol. Res. 305(3), 197–204 (2013). doi:10.1007/s00403-012-1309-2 PubMedCrossRef

10.

Currie, C.J., Conway, P.: Evaluation of the association between EQ5D utility and dermatology life quality index (DLQI) score in patients with psoriasis. Value Health 10(6), A470 (2007)CrossRef

11.

Hjortsberg, C., Bergman, A., Bjarnason, A., Heikkila, H., Hjelmgren, J., Svensson, A., Tennvall, G.R.: Are treatment satisfaction, quality of life, and self-assessed disease severity relevant parameters for patient registries? Experiences from Finnish and Swedish patients with psoriasis. Acta Derm. Venereol. 91(4), 409–414 (2011). doi:10.2340/00015555-1094 PubMedCrossRef

12.

Dolan, P.: Modeling valuations for EuroQol health states. Med. Care 35(11), 1095–1108 (1997)PubMedCrossRef

13.

Finlay, A.Y., Khan, G.K.: Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin. Exp. Dermatol. 19(3), 210–216 (1994)PubMedCrossRef

14.

Basra, M.K., Fenech, R., Gatt, R.M., Salek, M.S., Finlay, A.Y.: The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results. Br. J. Dermatol. 159(5), 997–1035 (2008). doi:10.1111/j.1365-2133.2008.08832.x PubMed

15.

Cohen, J.: A power primer. Psychol. Bull. 112, 155–159 (1992)PubMedCrossRef

16.

Balogh, O., Brodszky, V., Gulácsi, L., Herédi, E., Herszényi, K., Jókai, H., Kárpáti, S., Baji, P., Remenyik, É., Szegedi, A., Holló, P.: Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres. Eur. J. Health Econ. (2014). doi:10.1007/s10198-014-0599-z

17.

Mabuchi, T., Yamaoka, H., Kojima, T., Ikoma, N., Akasaka, E., Ozawa, A.: Psoriasis affects patient’s quality of life more seriously in female than in male in Japan. Tokai J. Exp. Clin. Med. 37(3), 84–88 (2012)PubMed

18.

Nijsten, T., Meads, D.M., de Korte, J., Sampogna, F., Gelfand, J.M., Ongenae, K., Evers, A.W., Augustin, M.: Cross-cultural inequivalence of dermatology-specific health-related quality of life instruments in psoriasis patients. J. Invest. Dermatol. 127(10), 2315–2322 (2007). doi:10.1038/sj.jid.5700875 PubMedCrossRef

19.

Mattei, P.L., Corey, K.C., Kimball, A.B.: Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J. Eur. Acad. Dermatol. Venereol. (2013). doi:10.1111/jdv.12106 PubMed

20.

Robinson, A., Kardos, M., Kimball, A.B.: Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J. Am. Acad. Dermatol. 66(3), 369–375 (2012). doi:10.1016/j.jaad.2011.01.022 PubMedCrossRef

21.

Revicki, D.A., Jin, Y., Wilson, H.D., Chau, D., Viswanathan, H.N.: Reliability and validity of the psoriasis symptom inventory in patients with moderate-to-severe psoriasis. J. Dermatolog. Treat. 25(1), 8–14 (2014). doi:10.3109/09546634.2013.769042 PubMedCrossRef

22.

Dauden, E., Herrera, E., Puig, L., Sanchez-Carazo, J.L., Toribio, J., Caloto, M.T., Nocea, G., Roset, M., Lara, N.: Validation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire. Health Qual. Life Outcomes 10, 56 (2012). doi:10.1186/1477-7525-10-56 PubMedCentralPubMedCrossRef

23.

Brodszky, V., Pentek, M., Balint, P.V., Geher, P., Hajdu, O., Hodinka, L., Horvath, G., Koo, E., Polgar, A., Sesztak, M., Szanto, S., Ujfalussy, I., Gulacsi, L.: Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey. Scand. J. Rheumatol. 39(4), 303–309 (2010). doi:10.3109/03009740903468982 PubMedCrossRef

24.

Dauden, E., Herrera, E., Puig, L., Sanchez-Carazo, J.L., Toribio, J., Perulero, N.: Impact of active and stable psoriasis on health-related quality of life: the PSO-LIFE study. Actas Dermosifiliogr. 104(8), 685–693 (2013). doi:10.1016/j.adengl.2013.02.008 PubMedCrossRef

25.

Pettey, A.A., Balkrishnan, R., Rapp, S.R., Fleischer, A.B., Feldman, S.R.: Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J. Am. Acad. Dermatol. 49(2), 271–275 (2003)PubMedCrossRef

26.

Sampogna, F., Tabolli, S., Abeni, D.: Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life. Acta Derm. Venereol. 92(3), 299–303 (2012). doi:10.2340/00015555-1273 PubMedCrossRef

27.

Sampogna, F., Chren, M.M., Melchi, C.F., Pasquini, P., Tabolli, S., Abeni, D.: Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis. Br. J. Dermatol. 154(2), 325–331 (2006). doi:10.1111/j.1365-2133.2005.06909.x PubMedCrossRef

28.

Lesuis, N., Befrits, R., Nyberg, F., van Vollenhoven, R.F.: Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study. BMC Med. 10, 82 (2012). doi:10.1186/1741-7015-10-82 PubMedCentralPubMedCrossRef

29.

Lu, G., Brazier, J.E., Ades, A.E.: Mapping from disease-specific to generic health-related quality-of-life scales: a common factor model. Value Health 16(1), 177–184 (2013). doi:10.1016/j.jval.2012.07.003 PubMedCrossRef

30.

Brazier, J.E., Yang, Y., Tsuchiya, A., Rowen, D.L.: A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur. J. Health Econ. 11(2), 215–225 (2010). doi:10.1007/s10198-009-0168-z PubMedCrossRef

31.

Shikiar, R., Willian, M.K., Okun, M.M., Thompson, C.S., Revicki, D.A.: The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual. Life Outcomes 4, 71 (2006). doi:10.1186/1477-7525-4-71 PubMedCentralPubMedCrossRef

Title: Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary
Authors: Emese Herédi
Fanni Rencz
Orsolya Balogh
László Gulácsi
Krisztina Herszényi
Péter Holló
Hajnalka Jókai
Sarolta Kárpáti
Márta Péntek
Éva Remenyik
Andrea Szegedi
Valentin Brodszky
Publication date: 01-05-2014
Publisher: Springer Berlin Heidelberg
Published in: The European Journal of Health Economics / Issue Special Issue 1/2014
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-014-0600-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary

Abstract

Background

Objectives

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Special Issue 1/2014

Biological and biosimilar therapies in inflammatory conditions: challenges for the Central and Eastern European countries

Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison

Economic burden of long-term care of rheumatoid arthritis patients in Hungary

Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics

Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres

Changes in the health status of the population of Central and Eastern European countries between 1990 and 2010